Treatment of humoral rejection in kidney transplantation

Transplantation Reviews

Volumn 20, Issue 2, 2006, Pages 95-103

  Crespo, Marta ^a   Oppenheimer, Federico ^a   Venetz, Jean Pierre ^b   Pascual, Manuel ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BELATACEPT; CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C4D; CYCLOSPORIN; EVEROLIMUS; HLA ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BLOOD GROUP ABO INCOMPATIBILITY; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; DESENSITIZATION; DISEASE SEVERITY; DONOR; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENTERIC COATED TABLET; HIGH RISK PATIENT; HUMAN; HUMORAL IMMUNITY; IMMUNOADSORPTION; IMMUNOTHERAPY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; PLASMAPHERESIS; PROTEINURIA; REOPERATION; T LYMPHOCYTE ACTIVATION;

EID: 33746261521     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2006.05.005     Document Type: Article

References (99)

1. Porter K.A., Thomson W.B., Owen K., et al. Obliterative vascular changes in four human kidney homotransplants. Br Med J 5358 (1963) 639-645
2. Kissmeyer-Nielsen F., Olsen S., Posborg Petersen V., and Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1 (1966) 662-665
3. Williams G.M., Hume D.M., Hudson Jr. R.P., et al. "Hyperacute" renal-homograft rejection in man. N Engl J Med 279 (1968) 611-618
4. Starzl T.E., Lerner R.A., Dixon F.J., et al. Shwartzman reaction after human renal homotransplantation. N Engl J Med 278 (1968) 642-648
5. Patel R., and Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280 (1969) 735-739
6. Jeannet M., Pinn V.W., Flax M.H., et al. Humoral antibodies in renal allotransplantation in man. N Engl J Med 282 (1970) 111-117
7. Austen K.F., and Russell P.S. Detection of renal allograft rejection in man by demonstration of a reduction in the serum concentration of the second component of complement. Ann N Y Acad Sci 129 (1966) 657-672
8. Halloran P.F., Wadgymar A., Ritchie S., et al. The significance of anti-class I antibody response. I. Clinical and pathologic features of anti-class I mediated rejection. Transplantation 49 (1990) 85-91
9. Halloran P.F., Schlaut J., Solez K., and Srinivasa N.S. The significance of anti-class I antibody response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 53 (1992) 550-555
10. Trpkov K., Campbell T., Pazderka F., et al. Pathologic features of acute renal allograft rejection associated with donor-specific antibody. Transplantation 61 (1996) 1586-1592
11. Feucht H.E., Felber E., Gokel M.J., et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 86 (1991) 464-470
12. Feucht H.E., Schneeberger H., Hillebrand G., et al. Capillary deposition of C4d complement fragment and early graft loss. Kidney Int 43 (1993) 1333-1338
13. Collins A.B., Schneeberger E.E., Pascual M., et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 10 (1999) 2208-2214
14. Crespo M., Delmonico F., Saidman S., et al. Acute humoral rejection in kidney transplantation. Graft 3 (2000) 12-17
15. Crespo M., Pascual M., Tolkoff-Rubin N., et al. Acute humoral rejection in renal allograft recipients: incidence, serology and clinical characteristics. Transplantation 71 (2001) 652-658
16. Mauiyyedi S., Crespo M., Collins A.B., et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology and pathologic classification. J Am Soc Nephrol 13 (2002) 779-787
17. Bohmig G.A., Exner M., Habicht A., et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 13 (2002) 1091-1099
18. Racusen L.C., Colvin R.B., Solez K., et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 3 (2003) 708-714
19. Michaels P.J., Fishbein M.C., and Colvin R.B. Humoral rejection of human organ transplants. Springer Semin Immunopathol 25 (2003) 119-140
20. Rotman S., Collins A.B., and Colvin R.B. C4d deposition in allografts: current concepts and interpretation. Transplant Rev 19 (2005) 65-77
21. Crespo M., Sole M., Arostegui J.L., et al. Diagnostic value of C4d in renal allograft biopsies in different clinical settings: absence of C4d in grafts from non-heart-beating-donors. Transplant Proc 37 (2005) 3688-3689
22. Moll S., and Pascual M. Humoral rejection of organ allografts. Am J Transplant 5 (2005) 2611-2618
23. Pascual M., Saidman S., Tolkoff-Rubin N., et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 66 (1998) 1460-1464
24. Herzenberg A.M., Gill J.S., Djurdjev O., and Magil A.B. C4d deposition in acute rejection: an independent long-term prognostic factor. J Am Soc Nephrol 13 (2002) 234-241
25. Lederer S.R., Schneeberger H., Albert E., et al. Early renal graft dysfunction. The role of preformed antibodies to DR-typed lymphoblastoid cell lines. Transplantation 61 (1996) 313-319
26. Karpinski M., Rush D., Jeffery J., et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 12 (2001) 2807-2814
27. Terasaki P.I. Humoral theory of transplantation. Am J Transplant 3 (2003) 665-673
28. Perrey C., Brenchley P.E., Johnson R.W., and Martin S. An association between antibodies specific for endothelial cells and renal transplant failure. Transpl Immunol 6 (1998) 101-106
29. Sumitran-Holgersson S., Wilczek H.E., Holgersson J., and Soderstrom K. Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 74 (2002) 268-277
30. Baldwin W.M., and Halloran P.F. Clinical syndromes associated with antibody in allografts. In: Racusen L.C., Solez K., and Burdick J.F. (Eds). Kidney transplant rejection. 3rd ed (1998), Marcel Decker, New York (NY) 127-147
31. Hill P., Gagliardini E., Ruggenenti P., et al. Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy. Nephrol Dial Transplant 20 (2005) 1741-1744
32. Weinstein D., Braun W.E., Cook D., et al. Ultra-late antibody-mediated rejection 30 years after a living-related renal allograft. Am J Transplant 5 (2005) 2576-2581
33. Baid S., Tolkoff-Rubin N., Saidman S., et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 3 (2003) 74-78
34. Takahashashi K., Saito K., Takahara S., et al. Japanese ABO-incompatible kidney transplantation committee. Excellent long-term outcome of ABO incompatible living donor kidney transplantation in Japan. Am J Transplant 4 (2004) 1089-1096
35. Warren D.S., Zachary A.A., Sonnenday C.J., et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 4 (2004) 561-568
36. Tyden G., Kumlienj G., Genberg H., et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 5 (2005) 145-148
37. Montgomery R.A., and Zachary A.A. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 8 (2004) 535-542
38. Takahashi K. A new concept of accommodation in ABO incompatible kidney transplantation. Clin Transplant 19 (2005) 76-85
39. Pascual M., Swinford R.D., Ingelfinger J.R., et al. Chronic rejection and chronic cyclosporine toxicity in renal allografts. Immunol Today 19 (1998) 514-519
40. Pascual M., Theruvath T., Kawai T., Tolkoff-Rubin N., and Cosimi A.B. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 346 (2002) 589-590
41. Davenport A., Younie M.E., Parsons J.E., and Klouda P.T. Development of cytotoxic antibodies following renal allograft transplantation is associated with reduced graft survival due to chronic vascular rejection. Nephrol Dial Transplant 9 (1994) 1351-1359
42. Abe M., Kawai T., Futatsuyama K., et al. Postoperative production of antidonor antibody and chronic rejection in renal transplantation. Transplantation 63 (1997) 1616-1619
43. Theruvath T.P., Saidman S.L., Mauiyyedi S., et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 72 (2001) 77-83
44. Lee P.C., Terasaki P.I., Takemoto S.K., et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 74 (2002) 1192-1194
45. Opelz G. Collaborative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 365 (2005) 1570-1576
46. Mauiyyedi S., Pelle P., Saidman S., et al. Chronic humoral rejection: identification of antibody mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 12 (2001) 574-582
47. Regele H., Böhmig G.A., Habicht A., et al. Capillary deposition of complement split product C4d in renal allograft is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 13 (2002) 2371-2380
48. Moll S., and Pascual M. Detection of alloantibody deposition in allografts: capillary C4d deposition as a marker of humoral rejection. Curr Opin Organ Transpl 9 (2004) 29-35
49. Cardarelli F., Pascual M., Tolkoff-Rubin N., et al. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int 18 (2005) 532-540
50. Terasaki P.I., and Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 4 (2004) 438-443
51. Worthington J.E., Martin S., Al-Husseini D.M., et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 75 (2003) 1034-1040
52. Montgomery R.A., Zachary A.A., Racusen L.C., et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match positive recipients. Transplantation 70 (2000) 887-895
53. Crespo M., Lozano M., Solé M., et al. Diagnosis and treatment of acute humoral rejection after kidney transplantation (AHR): a preliminary experience. Transplant Proc 35 (2003) 677-678
54. Jordan S.C., Quartel A.W., Czer L.S.C., et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 66 (1988) 800-805
55. Rocha P.N., Butterly D.W., Greenberg A., et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 75 (2003) 1490-1495
56. White N.B., Greenstein S.M., Cantafio A.W., et al. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 78 (2004) 772-774
57. Bohmig G.A., Regele H., Exner M., et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol 12 (2001) 2482-2489
58. Ibernon M., Gil-Vernet S., Carrera M., et al. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transplant Proc 37 (2005) 3743-3745
59. Becker Y.T., Becker B.N., Pirsch J.D., et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 4 (2004) 996-1001
60. Malik S.T., Churcher P., Sweny P., et al. Renal transplantation after removal of anti-HLA antibodies. Lancet 26 (1984) 1185
61. Taube D., Palmer A., Welsh K., et al. Removal of anti-HLA antibodies prior to transplantation: an effective and successful strategy for highly sensitised renal allograft recipients. Transplant Proc 21 (1989) 694-695
62. Higgins R.M., Bevan D.J., Carey B.S., et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 348 (1996) 1208-1211
63. Brocard J.F., Farahmand H., Fassi S., et al. Attempt at depletion of anti-HLA antibodies in sensitized patients awaiting transplantation using extracorporeal immunoadsorption, polyclonal IgG, and immunosuppressive drugs. Transplant Proc 21 (1989) 733-734
64. Ruiz J.C., de Francisco A.L., Vazquez de Prada J.A., et al. Successful heart transplantation after anti-HLA antibody removal with protein-A immunoadsorption in a hyperimmunized patient. J Thorac Cardiovasc Surg 107 (1994) 1366-1367
65. Casadei D.H., Rial M.C., Raimondi E., et al. Complementary data about the inhibitory effects of intravenous immunoglobulins in vitro and in vivo. Transplantation 63 (1997) 1191-1192
66. Jordan S.C., Vo A.A., Peng A., et al. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 6 (2006) 459-466
67. Glotz D., Antoine C., and Dubost A. Antidonor antibodies and transplantation: how to deal with them before and after transplantation. Transplantation 79 (2005) S30
68. Jordan S.C., Tyan D., Stablein D., et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 15 (2004) 3256-3262
69. SivaSai K.S., Mohanakumar T., Phelan D., et al. Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates. Clin Exp Immunol 119 (2000) 559-565
70. Stegall M.D., Gloor J., Winters J.M., et al. A comparison of plasmapheresis versus high dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6 (2006) 346-351
71. Pascual M., Duchosal M.A., Steiger G., et al. Circulating soluble CR1 (CD35). Serum levels in diseases and evidence for its release by human leukocytes. J Immunol 151 (1993) 1702-1711
72. Zimmerman J.L., Dellinger R.P., Straube R.C., et al. Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med 28 (2000) 3149-3154
73. Pierson III R.N., Loyd J.E., Goodwin A., et al. Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy. Transplantation 74 (2002) 79-84
74. Ahsan N., Holman M.J., Katz D.A., et al. Successful reversal of acute vascular rejection in a renal allograft with combined mycophenolate mofetil and tacrolimus as primary immunotherapy. Clin Transplant 11 (1997) 94-97
75. The Mycophenolate Mofetil Renal Refractory Rejection Study Group 2,3. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection 1. Transplantation 61 (1996) 722-729
76. Lafferty M.E., Lang S., McGregor E., et al. Treatment of severe acute vascular rejection in a renal allograft with mycophenolate mofetil and high dose steroids. Scott Med J 42 (1997) 79-80
77. Smith K.G., Isbel N.M., Catton M.G., et al. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 13 (1998) 160-164
78. Broeders N., Wissing K.M., Crusiaux A., et al. Mycophenolate mofetil, together with cyclosporine A, prevents anti-OKT3 antibody response in kidney transplant recipients. J Am Soc Nephrol 9 (1998) 1521-1525
79. Anderson J.B., Fuller T.C., Hawkins J.A., et al. Two-year reduction of panel reactive human leukocyte antigen antibodies in children receiving mycophenolate mofetil after valved allograft placement. Transplantation 80 (2005) 414-416
80. Vieira C.A., Agarwal A., Book B.K., et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77 (2004) 542-548
81. Tyden G., Kumlien G., and Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 76 (2003) 730-731
82. Gloor J.M., DeGoey S.R., Pineda A.A., et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 3 (2003) 1017-1023
83. Aranda Jr. J.M., Scornik J.C., Normann S.J., et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation 73 (2002) 907-910
84. Garret H.E., Groshart K., Duval-Searman D., et al. Treatment of acute humoral rejection with rituximab. Ann Thorac Surg 74 (2002) 1240-1242
85. Crespo M., Arostegui J.J., Esforzado N., et al. A liver graft does not always protect a kidney graft from acute humoral rejection in combined transplantation. Transplant Int 18 Suppl 1 (2005) 44
86. Genberg H., Hansson A., Wernerson A., and Tyden G. Effective B-cell depletion in peripheral blood and tissue by single-dose rituximab in kidney transplant recipients: a pilot study. Am J Transplant 11 S11 (2005) 397
87. Bearden C.M., Agarwal A., Book B.K., et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 5 (2005) 50-57
88. Tokunaga M., Fujii K., Saito K., et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology 44 (2005) 176-182
89. Jordan M.L., Naraghi R., Shapiro R., et al. Tacrolimus rescue therapy for renal allograft rejection-five-year experience. Transplantation 63 (1997) 223-228
90. Loss Jr. G.E., Grewal H.P., Siegel C.T., et al. Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen. Transplant Proc 30 (1998) 1249-1250
91. Jurcevic S., Dunn M.J., Crisp S., et al. A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. Transplantation 65 (1998) 1197-1202
92. Vincenti F. Protein therapies and antiproliferatives: a new paradigm in immunosuppression. Transplant Rev 19 (2005) 179-185
93. Beniaminovitz A., Itescu S., Lietz K., et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 342 (2000) 613-619
94. Knechtle S.J., Pirsch J.D., Fechner Jr. J., et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 3 (2003) 722-730
95. Hill P., Gagliardini E., Ruggenenti P., and Remuzzi G. Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy. Nephrol Dial Transplant 20 (2005) 1741-1744
96. Sunders R.N., Matcalfe M.S., and Nicholsan M.L. Rapamycin in transplantation: a review of the evidence. Kidney Int 59 (2001) 3-16
97. Aagaard-Tillery K.M., and Jelinek D.F. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol 156 (1994) 493-507
98. Pescovitz M.D., Book B.K., Henson S., et al. The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulin. Am J Transplant 3 (2003) 497-500
99. Diekmann F., Budde K., Oppenheimer F., et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4 (2004) 1869-1875